Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
According to WHO, over 1.5 million people died of TB in 2020
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
At present 18 per cent of the local pharmaceutical market is under government's price control
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
PPH is associated with almost 20 per cent of maternal mortality in India
Subscribe To Our Newsletter & Stay Updated
